Enzo Biochem Net Income 2010-2022 | ENZ

Enzo Biochem net income from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Enzo Biochem Annual Net Income
(Millions of US $)
2022 $-18
2021 $8
2020 $-29
2019 $2
2018 $-10
2017 $-3
2016 $45
2015 $-2
2014 $-10
2013 $-18
2012 $-39
2011 $-13
2010 $-22
2009 $-24
Enzo Biochem Quarterly Net Income
(Millions of US $)
2022-10-31 $-11
2022-07-31 $-8
2022-04-30 $-5
2022-01-31 $-3
2021-10-31 $-2
2021-07-31 $3
2021-04-30 $2
2021-01-31 $2
2020-10-31 $0
2020-07-31 $-3
2020-04-30 $-10
2020-01-31 $-8
2019-10-31 $-8
2019-07-31 $-5
2019-04-30 $22
2019-01-31 $-8
2018-10-31 $-6
2018-07-31 $-6
2018-04-30 $-3
2018-01-31 $-1
2017-10-31 $-1
2017-07-31 $0
2017-04-30 $-0
2017-01-31 $-1
2016-10-31 $-1
2016-07-31 $36
2016-04-30 $-2
2016-01-31 $7
2015-10-31 $4
2015-07-31 $8
2015-04-30 $-3
2015-01-31 $-4
2014-10-31 $-4
2014-07-31 $-3
2014-04-30 $-0
2014-01-31 $-4
2013-10-31 $-3
2013-07-31 $-3
2013-04-30 $-6
2013-01-31 $-6
2012-10-31 $-4
2012-07-31 $-27
2012-04-30 $-3
2012-01-31 $-4
2011-10-31 $-4
2011-07-31 $-4
2011-04-30 $-2
2011-01-31 $-6
2010-10-31 $-1
2010-07-31 $-6
2010-04-30 $-5
2010-01-31 $-10
2009-10-31 $-2
2009-07-31 $-5
2009-04-30 $-4
2009-01-31 $-8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.066B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.446B 9.24
GSK (GSK) United Kingdom $72.652B 9.59
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.227B 19.16
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.620B 24.32
Biohaven (BHVN) United States $1.283B 0.00
Emergent Biosolutions (EBS) United States $0.681B 5.35
ADC Therapeutics SA (ADCT) Switzerland $0.419B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00